Process for the treatment of practically anhydrous compsns. contg. the blood coagulation factor, Factor VIII, to reduce or eliminate any risk of infection due to microorganisms present in the compsn., comprises heating the compsn. for a predetermined period, at a sufficient predetermined temp. to reduce or suppress the infectious ability of the microorganism. - Compsns. contg. inactivated microorganisms and Factor VIII obtd. by the above process and Hepatitis vaccines, which contain an effective immunogenic amt. of inactivated hepatitis virus, which has been inactivated in a blood plasma fraction, with a suitable vehicle are also claimed. - Used in the treatment of blood plasma to avoid transmission of infections due to microorganisms e.g. hepatitis, whilst retaining the activity of the coagulation factors. The compsns. are partic. useful in the treatment of haemophilics. Also used in the prepn. of vaccines against hepatitis B and hepatitis non-A non-B.    (Dwg.0/0) EPAB- EP--94611 B An AHF enriched composition for the mfr. of a medicament agent for the treatment of bleeding disorders; said composition comprising a human Factor VIII concentrate essentially free of blood clotting enzymes and having been treated by heating for a predetermined period of time in the lyphilised form at a temp. of at least 60 deg.C, characterised by said human Factor VIII having both prior to and after heating an AHF purity of greater than about 300 AHF units/gram of protein by said composition being heated to render susbtantially inactive a virus related to Acquired Immune Deficiency Syndrome (AIDS) and said AIDS virus being rendered substantially inactive.  (11pp)z GBAB- GB2120254 B A method for treating a substantially dry composition including Factor VIII to reduce or eliminate the infectivity of the microorganisms present in the composition comprising heating the composition for a predetermined period of time at a predetermined temperature sufficient to reduce or eliminate the infectivity of the microorganisms. - GB2144428 B An AHF enriched composition for the manufacture of a medicament agent for the treatment of bleedinq disorders; said composition comprising a human Factor VIII concentrate essentially free of blood clotting enzymes and containing at least a substantially non-infectious virus related to Acquired Immune Deficiency Syndrome (AIDS), said AIDS-related virus having been rendered substantially inactive by heating said composition for a predetermined period of time in the lyophilised form at a temperature of at least 60 deg.C, and said human Factor VIII having both prior to and after heating a relative specific activity in units of AHF to any individual blood clotting enzyme of more than about 10:1. USAB- US4456590 A Treatment of blood clotting factor VIII concentrate, to minimise effect of any hepatitis virus present, comprises (i) lyphophilising; and (ii) heating at predetermined temp. of at least 60 deg. C. for sufficient time to render hepatitis virus non infections, heating generally decreasing as temp. is increased. - Pref. temp is 60-100 deg. C.  Pref. sterile water is added to lyphophilised blood Factor VIII, following heating step until solubilisation is achieved.